Future Prospects for Cancer Immunotherapy Using Induced Pluripotent Stem Cell-Derived Dendritic Cells or Macrophages.
Satoshi FukushimaAzusa MiyashitaHaruka KuriyamaToshihiro KimuraSatoru MizuhashiYosuke KuboSatoshi NakaharaHisashi KanemaruNobuhiro TsuchiyaHiroaki MashimaRong ZhangYasushi UemuraPublished in: Experimental dermatology (2022)
Cancer immunotherapy is now the first-line treatment for many unresectable cancers. However, it remains far from a complete cure for all patients. Therefore, it is necessary to develop innovative methods for cancer immunotherapy, and immune cell therapy could be an option. Currently, several institutions are attempting to generate immune cells from induced pluripotent stem cells (iPSCs) for use in cancer immunotherapy. A method for generating dendritic cells (DCs) and macrophages (MPs) from iPSC has been established. iPSC-derived DCs (iPS-DCs) can activate T cells via antigen presentation, and iPSC-derived macrophages (iPS-MPs) attack cancer. Since iPSCs are used as the source, genetic modification is easy, and various immune functions, such as the production of anti-tumor cytokines, can be added. Furthermore, when iPS-DCs and iPS-MPs are immortalized, cost reduction through mass production is theoretically possible. In this review, the achievements of cancer research using iPS-DCs and iPS-MPs are summarized, and the prospects for the future are discussed.
Keyphrases
- induced pluripotent stem cells
- dendritic cells
- cell therapy
- current status
- papillary thyroid
- end stage renal disease
- immune response
- squamous cell
- newly diagnosed
- regulatory t cells
- chronic kidney disease
- ejection fraction
- stem cells
- mesenchymal stem cells
- peritoneal dialysis
- gene expression
- prognostic factors
- genome wide
- lymph node metastasis
- radiation therapy
- dna methylation
- locally advanced
- oxidative stress